¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

[¿Â¶óÀÎ] Á¦23ȸ Çѱ¹Æ÷µµ¸·ÇÐȸ ½ÉÆ÷Áö¾ö : 2022-05-14

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
[¿Â¶óÀÎ] Á¦23ȸ Çѱ¹Æ÷µµ¸·ÇÐȸ ½ÉÆ÷Áö¾ö : 2022-05-14
±³À°ÀÏÀÚ : 2022-05-14
±³À°Àå¼Ò : ¿Â¶óÀÎ ½ºÆ®¸®¹Ö  
±³À°ÁÖÁ¦ : [¿Â¶óÀÎ] Á¦23ȸ Çѱ¹Æ÷µµ¸·ÇÐȸ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹Æ÷µµ¸·ÇÐȸ  
´ã´çÀÚ : Á¤À¯¸®
¿¬¶ôó : 031-219-7815  
À̸ÞÀÏ : cyr216@hanmail.net      
±³À°Á¾·ù : ¾È°ú      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í Á¤È¸¿ø(ȸºñ ¿Ï³³ ½Ã): ¹«·á / ºñȸ¿øÀü¹®ÀÇ: 50,000¿ø Àü°øÀÇ, °ü°èÀÚ: 20,000¿ø  ÀÇÇù È®Àοë ID:kma / PW: 1234      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-14  09:00~09:12 Dilemma in Real-world Clinical Practice: Anterior Uveitis  ¹Úö¿ë(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 05-14  09:12~09:24 Dilemma in Real-world Clinical Practice: Posterior Uveitis  ¿ì¼¼ÁØ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-14  09:24~09:36 HLA Associated Ocular Inflammatory Diseases  Á¤Çý¿ø(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 05-14  09:36~09:48 Drug Delivery and Local Therapies for Uveitis  ÀÌÁ¾Çö(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 05-14  09:48~10:00 Establishing the Evidence: Key Clinical Trials in Uveitis  ¾ÈÁöÀ±(¼­¿ïÀÇ´ë) 
Åä·Ð 05-14  10:00~10:20 Q&A  ÁÂÀå(ÀÌÁ¾Çõ/À¯½Â¿µ)(¿øÁÖÀÇ´ë/°æÈñÀÇ´ë) 
±³À°½Ã°£ 05-14  10:25~10:45 Immune Response to COVID-19 or Vaccination  ¹Ú¿Ï¹ü(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-14  10:45~11:00 COVID-19-related Anterior Inflammation  ±è¹Ì±Ý(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-14  11:00~11:15 COVID-19-related Posterior Inflammation  À̽±Ô(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 05-14  11:15~11:30 Treatment of Uveitis in COVID-19 Patients  ¹èÁ¤ÈÆ(¼º±Õ°üÀÇ´ë) 
Åä·Ð 05-14  11:30~11:50 Q&A  ÁÂÀå(ÇÔµ·ÀÏ/¼­°æ·ü)(¼º±Õ°üÀÇ´ë/¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 05-14  12:40~12:55 Ocular Surface Complications in Uveitis  ±èÀ¯Á¤(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 05-14  12:55~13:10 Cataract in Uveitis  ±è°æ¿ì(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 05-14  13:10~13:25 Glaucoma in Uveitis  ÇϾƴÃ(Á¦ÁÖÀÇ´ë) 
±³À°½Ã°£ 05-14  13:25~13:40 Uveitic Macular Edema  ÀÌÁÖ¿ë(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 05-14  13:40~13:55 Vitreoretinal Complications in Uveitis  ±è¹Î(¿¬¼¼ÀÇ´ë) 
Åä·Ð 05-14  13:55~14:15 Q&A  ÁÂÀå(À̼ºÃ¶/ÀÌÇü±Ù)(°Ç¾çÀÇ´ë/¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 05-14  14:20~14:30 Infectious Scleritis  ÀüÀÍÇö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 05-14  14:30~14:40 °©Àڱ⠴«ÀÌ º×°í ¾ÆÆļ­ ³»¿øÇÑ 60¼¼ SLE ȯÀÚ  À̱âȲ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 05-14  14:40~14:50 Endogenous Endophthalmitis: Round Up the Usual Suspects  À±Ã¶¹Î(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 05-14  14:50~15:00 ´« ¸Åµ¶¿¡ µ¿¹ÝµÈ °ßÀθÁ¸·¹Ú¸®  ±ÇÀ±Çü(µ¿¾ÆÀÇ´ë) 
±³À°½Ã°£ 05-14  15:00~15:10 Impact of Optic Disc Hyperfluorescence on Retina and Optic Nerve Head Thickness in Patients with Uveitis  ¹è°ÇÈ£(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-14  15:10~15:20 Retinal Vasculitis  ¹Ú¿µÁÖ(°­¿øÀÇ´ë) 
±³À°½Ã°£ 05-14  15:20~15:30 Floating Cysticercosis Cyst  ±è¿ëÁØ(¿¬¼¼ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" [¿Â¶óÀÎ] Á¦23ȸ Çѱ¹Æ÷µµ¸·ÇÐȸ ½ÉÆ÷Áö¾ö : 2022-05-14""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ)2022³â Á¦4Â÷ ½ºÆ÷Ã÷ÀÇÇÐ ÆÀÁÖÄ¡ÀÇ ½ÉÈ­±³À°°úÁ¤ : 2022-05-14
´ÙÀ½±Û ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ (¿Â¶óÀÎ) 2022³â Á¦1Â÷ ÇÁ·ÎÆ÷Æú ÁøÁ¤±³À° : 2022-05-14
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20805 ¼­¿ï 2024 ´ëÇÑ»ê°ú¸¶ÃëÇÐȸ Á¦27Â÷ Çмú´ëȸ : 2024-06-15 0 4 2024-05-27
20804 ÃæºÏ 204 ÃæûºÏµµÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-06-15 0 8 2024-05-27
20803 ºÎ»ê 2024³â Á¦7ȸ ´ëÇÑÁßȯÀÚÀçÈ°ÇÐȸ Áý´ãȸ : 2024-06-15 0 3 2024-05-27
20802 ºÎ»ê 2024³â ´ëÇÑÁßȯÀÚÀçÈ°ÇÐȸ ¿öÅ©¼¥-±â´ÉÀû Æò°¡ ¹× ÁßȯÀÚ ÀçÈ°ÀÇ ½ÇÁ¦ (¿Ü»ó ÁßȯÀÚ Æ÷ÇÔ) : 2024-06-15 0 6 2024-05-27
20801 ¼­¿ï KLASS 20Áֳ⠱â³ä 2024 ´ëÇѺ¹°­°æÀ§Àå°ü¿¬±¸È¸ Á¦27ȸ Á¤±âÇмú´ëȸ : 2024-06-15 0 3 2024-05-27
20800 °æ±â 2024³â Á¦ 3ȸ Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-15 0 8 2024-05-27
20799 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ ÀÓ»óÁø·áÁöħ Æò°¡À§¿ø ¾ç¼º±³À° : 2024-06-15 0 2 2024-05-27
20798 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾÆû¼Ò³â°ú ºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2024-06-15 0 1 2024-05-27
20797 ¼­¿ï ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ COPD School 2024 : 2024-06-15 0 1 2024-05-27
20796 ¼­¿ï »óóÀå·ç¿¬±¸È¸ Áý´ãȸ : 2024-06-15 0 2 2024-05-27
20795 Àü³² 2024³â Àü¶ó³²µµÀÇ»çȸ Àü¹Ý±â Çмú´ëȸ : 2024-06-15 0 3 2024-05-27
20794 ¼­¿ï Ç÷°ü¿µ»ó»ý¸®¿¬±¸È¸ IPOP(Imaging and Physiology on Patients with Cardiovascular Disease) 2024 : 2024-06-15 0 1 2024-05-27
20793 ¼­¿ï ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ ¾à¹°¾Ë·¹¸£±â ½ÉÆ÷Áö¾ö : 2024-06-15 0 3 2024-05-27
20792 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ´ëÀü, ÃæûÁöȸ - Á¦3Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-15 0 1 2024-05-27
20791 ¼­¿ï Á¦51ȸ ´ëÇÑÀÓ»óÇǺÎÄ¡·á¿¬±¸È¸ ±³À°½ÉÆ÷Áö¾ö : 2024-06-15 0 5 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷